01.07.2023 | BRIEF REPORT
Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study
Erschienen in: Clinical Rheumatology | Ausgabe 10/2023
Einloggen, um Zugang zu erhaltenAbstract
Key Points • Interstitial lung disease is a common manifestation of several connective tissue diseases and its progressive fibrosing phenotype contributes to high mortality rate and many unmet needs regarding the treatment remain. • Registration studies of nintedanib obtained sufficient data and positive results to support approval of the drug. • Real-world evidence from our CTD-ILD centres confirm the clinical trial data regarding efficacy, tolerability and safety of nintedanib. |